Regeneron Pharmaceuticals Inc.
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
20.59%
Market Cap
54.88 Bil.
P/E Ratio
18.61
Dividend Yield
0.46 %
Earnings per Share
36.77 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 532.7 G | 0 Units |
| PRICE DETERMINATION TIME | 06/03/2026 / 09:56:48 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 536.6 | 513 |
| PREV. DAY'S PRICE | 517.1 | (06/02) |
| CHANGE DAY BEFORE | +15.60 | 3.02 % |
| 52 WEEK HIGH / LOW | 700 (01/08) | 420.6 (06/05) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 47.41 | 40.67 | 36.77 | 35.44 | 32.16 |
| DIVIDENDS PER SHARE | 3.44 | 3.32 | 3.12 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.46 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | 11.23 | 13.09 | 18.61 | 18.58 | 25.26 |
| PRICE - BOOK RATIO | - | - | 2.61 | 2.66 | 3.70 |
| PRICE - SALES RATIO | - | - | 5.84 | 5.77 | 7.61 |
| PRICE - CASH FLOW RATIO | - | - | 16.84 | 18.55 | 21.74 |
Master Data
| WKN | 881535 |
| ISIN | US75886F1075 |
| SYMBOL | RGO |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Regeneron Pharmaceuticals |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 103.02 Mil. |
| MARKET CAPITALISATION | 54.88 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -4.98 % | -14.06 % | -23.35 % | -19.18 % | 20.59 % | -25.06 % | 25.27 % | -21.58 % |
| HIGH | 545.10 | 620.90 | 682.20 | 700.00 | 700.00 | 1,087.00 | 1,087.00 | 700.00 |
| LOW | 509.50 | 509.50 | 509.50 | 509.50 | 420.60 | 420.60 | 411.25 | 509.50 |
Dividend
per share
Company profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Structured products for Regeneron Pharmaceuticals Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.